Von Hippel-Lindau (VHL) disease is a multisystem genetic disease, the cardinal manifestations of which include central nervous system hemangioblastomas (CNS HB), renal cell carcinomas (RCC), and pheochromocytoma. Tumorigenesis in VHL of both RCC and CNS HB occurs secondary to downstream effects of a mutated or absent VHL protein. Treatment of RCCs with tyrosine kinase inhibitors (TKIs) such as Pazopanib is now first line therapy, but their effect on VHL-associated CNS HBs remains unknown. We report the use of Pazopanib in a patient with VHL disease for treatment of RCC who also harbored multiple CNS HBs. Following initiation of treatment, a large cervical and a lumbar spinal HB regressed in size while the remaining CNS HBs exhibited stable or progressive disease. These findings highlight the multiplicity of factors contributing to hemangioblastoma development, even among tumors with a common germline mutation, and the potential limitations of TKIs, but additionally this report supports the conservative management of asymptomatic VHL patients with spinal HBs whereby tumor response to TKI treatment may alleviate or postpone the need for surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jocn.2018.01.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Temporal Dynamics of Plasma Neurofilament Light in Blood Donors With Preclinical Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
January 2025
From the The Danish Multiple Sclerosis Centre (J.B., H.B.S., M.M., J.L.F.B., F.S.), Department of Neurology, Copenhagen University Hospital, Rigshospitalet; Department of Clinical Immunology (J.B., M.H.L., S.R.O., S.M.), Copenhagen University Hospital Rigshospitalet; Department of Clinical Medicine (J.B., M.M., O.B.P., S.R.O., J.L.F.B., F.S., S.M.), Faculty of Health and Medical Sciences, University of Copenhagen; Department of Health Technology (A.G.P.), Section for Bioinformatics, Technical University of Denmark; The Danish Cancer Institute (S.R.), Statistics and Data Analysis; The Danish Multiple Sclerosis Registry (M.M.); Department of Clinical Immunology (O.B.P.), Zealand University Hospital; Department of Clinical Immunology (B.A.J.), Aalborg University Teaching Hospital; Department of Clinical Immunology (C.E.), Aarhus University Teaching Hospital and Statens Serum Institut (H.U.), Copenhagen, Denmark.
Background And Objectives: Multiple sclerosis (MS) is a CNS disease, characterized by demyelination, inflammation, and neurodegeneration. Recent advances in technology allow measurement of the axonal damage marker neurofilament light chain in peripheral blood. Two studies have shown that patients with MS have elevated neurofilament light levels before their first symptom, but longitudinal studies are lacking.
View Article and Find Full Text PDFComparative analysis of stereotactic radiosurgery outcomes for supratentorial hemangioblastomas in von hippel-lindau disease and sporadic cases: A multi-center international study.
J Clin Neurosci
November 2024
Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA. Electronic address:
Background: Hemangioblastomas (HBs) are rare, benign central nervous system (CNS) neoplasms that rarely occur in the supratentorial. Resection with the goal of gross total resection (GTR) is often considered the primary treatment. Stereotactic radiosurgery (SRS) has been utilized more commonly in unresectable or partially resected cases.
View Article and Find Full Text PDFUnderstanding Adult Central Nervous System Hemangioblastomas: A Systematic Review.
World Neurosurg
November 2024
Semmes Murphey Neurologic & Spine Institute, Memphis, Tennessee, USA; Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Electronic address:
Background: Adult hemangioblastomas (HBs) are rare World Health Organization central nervous system (CNS) grade 1 tumors, particularly affecting the posterior cranial fossa. They exhibit a gender bias, impacting men in their fifth and sixth decades of life and manifesting sporadically or as part of von Hippel Lindau disease. Understanding the intricacies of CNS HBs is crucial for clinical decision-making.
View Article and Find Full Text PDFHydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.
Am J Hematol
October 2024
Department of Neurology and Neurosurgery, BIOS Clinical Trials Coordinating Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Central nervous system (CNS) injury is common in sickle cell disease (SCD) and occurs early in life. Hydroxyurea is safe and efficacious for treatment of SCD, but high-quality evidence from randomized trials to estimate its neuroprotective effect is scant. HU Prevent was a randomized (1:1), double-blind, phase II feasibility/pilot trial of dose-escalated hydroxyurea vs.
View Article and Find Full Text PDFRecurrent Tuberous Sclerosis Complex/Mammalian Target of Rapamycin Mutations Define Primary Renal Hemangioblastoma as a Unique Entity Distinct From Its Central Nervous System Counterpart.
Am J Surg Pathol
July 2024
Department of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing.
Renal hemangioblastoma (HB) is a rare subset of HBs arising outside of the central nervous system (CNS), with its molecular drivers remaining entirely unknown. There were no significant alterations detected in previous studies, including von Hippel-Lindau gene alterations, which are commonly associated with CNS-HB. This study aimed to determine the real molecular identity of renal HB and better understand its relationship with CNS-HB.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!